Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2018 Earnings Conference Call - Final Transcript

Mar 07, 2019 • 04:30 pm ET


Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2018 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good day, ladies and gentlemen, and thank you for standing by. We welcome you to Syndax Fourth Quarter and End of Year 2018 Earnings Call. At this time all participants are in a listen only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this conference call may be recorded.

I would now like to turn the conference over to Melissa Forst with Argot Partners. Please go ahead.

Melissa Forst

Thank you. Welcome, and thank you to those of you joining us today for Syndax's fourth quarter and 2018 full year financial and operating results conference call. Joining us this afternoon for prepared remarks will be Dr. Briggs Morrison, Chief Executive Officer; and Rick Shea, Chief Financial Officer. Also joining us on the call today for the question-and-answer session are Michael Metzger, President and Chief Operating Officer; Dr. Michael Meyers, Chief Medical Officer; and Dr. Peter Ordentlich, Chief Scientific Officer. This call is being accompanied by a slide deck that has been posted on the company's website, so I'd please ask you to turn to the forward-looking statements on Slide two.

Before we begin, I would like to remind you that any statement made during this call that is not historical is considered to be forward-looking in nature for the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various factors, including those discussed in the Risk Factors section of the company's most recent annual report on Form 10-K as well as other reports filed with the SEC. Any forward-looking statements represent the company's views as of today, March 7th, 2019, only. A replay of this call will be available on the company's website, following the call.

And with that, I am pleased to turn the call over to Dr. Morrison.

Briggs W. Morrison

Thank you very much, Melissa, and thank you to everyone who is joining us on today's call and webcast. As we closed out 2018 and entered 2019, we took the time to look back on what this management team has accomplished over the past three-and-a-half years. Our goal has been to build a pipeline of opportunities that will allow us to reach our mission, that will allow us to realize a future in which people with cancer live longer and better than ever before. And as we were closing out 2018, we concluded that we have too many opportunities for our company of our size and resources. And so through conversations with physicians, scientists, advisers and members of our board, we've prioritized our portfolio. The work was difficult. We've had many passionate advocates inside and outside our company for every one of our active programs, and we believe that all our active programs have potential to benefit patients. And yet we had to choose the ones we thought had the most potential. Today I'm going to share with you the results of that prioritization effort and explain